Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited

Generic Pharmaceuticals (Multiple Therapeutic Areas)

$70.0B US generics market 2014-15 (~$70-80B)

Disease Overview

Generic pharmaceuticals are off-patent equivalents of branded drugs that compete primarily on price and manufacturing scale. The category covers nearly every therapeutic area, with profitability driven by ANDA approvals, manufacturing quality (FDA cGMP compliance), and commercial channel access. Quality compliance is the dominant operational risk — Ranbaxy's pre-deal FDA consent decree underscores how plant-level issues can erase deal economics.

Competitive Landscape

The 2014-2015 global generics market was dominated by Teva (post-Cephalon, ~$20B revenue), Sandoz (Novartis), Mylan, Actavis (mid-merger with Forest, then later Allergan generics), and Pfizer's Greenstone, with Indian players Sun, Dr. Reddy's, Lupin, and Cipla scaling rapidly into US ANDAs. The Sun-Ranbaxy combination created the world's fifth-largest generic drug maker and India's largest pharma, with ~$4.5B pro-forma revenue and the broadest US ANDA portfolio of any Indian player. The strategic logic — geographic complementarity (Sun strong in chronic/specialty US, Ranbaxy strong in EM and acute care), Para-IV pipeline (Gleevec, Diovan, Nexium FTFs), and cost synergies of $250M targeted by year-three — was compelling, but Ranbaxy carried four FDA-banned plants and a $500M DOJ settlement legacy. Analysts at Emkay flagged Halol approvals and integration of Ranbaxy's India acute therapy business as near-term overhangs. The deal repositioned Sun against Teva and Mylan in the US generics top tier and gave Daiichi Sankyo (63.4% Ranbaxy holder) a clean exit after a disastrous 2008 acquisition. Post-close, FY15 EBITDA margins compressed from 45% to 32% as Ranbaxy's compliance burden weighed on consolidated economics.